文献速递心力衰竭与心肌病冠心病

当代乳腺癌放疗后老年女性射血分数保留的心力衰竭风险

Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer.
PubMed 文献 · Circulation · 2017-01-29

该研究在明尼苏达州奥姆斯特德县170名接受当代(1998-2013年)CT辅助放疗计划的女性乳腺癌患者中开展基于人群的病例对照研究(59例心衰病例和111例对照)。结果显示,心脏平均辐射剂量越高,任何心衰和射血分数保留的心衰(HFpEF)的比值比越高,且校正心衰危险因素后仍显著。

要点

  • 心衰病例中64%为射血分数保留的心衰(HFpEF),31%为射血分数降低的心衰。
  • 心脏平均辐射剂量每增加1个对数单位,任何心衰的比值比为9.1(95%CI 3.4-24.4),HFpEF为16.9(95%CI 3.9-73.7)。
  • 作者强调限制心脏平均辐射剂量的放疗技术重要性,并为HFpEF病理生理中冠状动脉微血管障碍提供支持。

核心结论

  • 当代适形乳腺癌放疗期间,心脏辐射暴露增加与HFpEF相对风险增加相关。
  • 这些数据强调限制心脏平均辐射剂量的放疗技术重要性,并为HFpEF病理生理中冠状动脉微血管障碍的重要性提供进一步支持。

研究设计与样本

  • 基于人群的病例对照研究,纳入170名明尼苏达州奥姆斯特德县女性居民(59例心衰病例和111例对照),均接受当代(1998-2013年)CT辅助放疗计划的乳腺癌放疗。
  • 对照按年龄、肿瘤侧别、化疗使用、糖尿病和高血压与病例匹配。
  • 每例患者的心脏平均辐射剂量(MCRD)根据其CT图像和放疗计划计算。

主要发现

  • 放疗时平均年龄为69±9岁。
  • 心衰病例中38例(64%)射血分数≥50%(HFpEF),18例(31%)射血分数<50%(射血分数降低的心衰),3例(5%)未测量射血分数。
  • 在56例有射血分数测量的心衰病例中,50例(89%)射血分数≥40%。
  • 从放疗到心衰的平均间隔为5.8±3.4年。
  • 有缺血性心脏病或心房颤动病史的患者心衰比值比更高。

关键数值与推荐

  • 心脏平均辐射剂量为2.5 Gy(范围0.2-13.1 Gy),病例组(3.3±2.7 Gy)高于对照组(2.1±2.0 Gy;P=0.004)。
  • 每对数MCRD的任何心衰比值比为9.1(95%CI 3.4-24.4),HFpEF为16.9(95%CI 3.9-73.7),射血分数降低的心衰为3.17(95%CI 0.8-13.0)。
  • 校正心衰危险因素后,以及以癌症分期而非肿瘤侧别匹配的敏感性分析中,任何心衰或HFpEF随MCRD增加的比值比仍显著。
  • 放疗至心衰发病期间,仅18.6%的患者发生新发或复发性缺血事件。

临床怎么用

  • 作者强调乳腺癌治疗期间限制心脏平均辐射剂量的放疗技术重要性。
  • 作者认为这些数据为HFpEF病理生理中冠状动脉微血管障碍的重要性提供进一步支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiomyocytes are resistant to radiation. However, cardiac radiation exposure causes coronary microvascular endothelial inflammation, a perturbation implicated in the pathogenesis of heart failure (HF) and particularly HF with preserved ejection fraction (HFpEF). Radiotherapy for breast cancer results in variable cardiac radiation exposure and may increase the risk of HF. METHODS: We conducted a population-based case-control study of incident HF in 170 female residents of Olmsted County, Minnesota (59 cases and 111 controls), who underwent contemporary (1998-2013) radiotherapy for breast cancer with computed tomography-assisted radiotherapy planning. Controls were matched to cases for age, tumor side, chemotherapy use, diabetes mellitus, and hypertension. Mean cardiac radiation dose (MCRD) in each patient was calculated from the patient's computed tomography images and radiotherapy plan. RESULTS: Mean age at radiotherapy was 69±9 years. Of HF cases, 38 (64%) had EF≥50% (HFpEF), 18 (31%) had EF<50% (HF with reduced EF), and 3 (5%) did not have EF measured. The EF was ≥40% in 50 of the 56 HF cases (89%) with an EF measurement. The mean interval from radiotherapy to HF was 5.8±3.4 years. The odds of HF was higher in patients with a history of ischemic heart disease or atrial fibrillation. The MCRD was 2.5 Gy (range, 0.2-13.1 Gy) and higher in cases (3.3±2.7 Gy) than controls (2.1±2.0 Gy; P=0.004). The odds ratio (95% confidence interval) for HF per log MCRD was 9.1 (3.4-24.4) for any HF, 16.9 (3.9-73.7) for HFpEF, and 3.17 (0.8-13.0) for HF with reduced EF. The increased odds of any HF or HFpEF with increasing MCRD remained significant after adjustment for HF risk factors and in sensitivity analyses matching by cancer stage rather than tumor side. Only 18.6% of patients experienced new or recurrent ischemic events between radiotherapy and the onset of HF. CONCLUSIONS: The relative risk of HFpEF increases with increasing cardiac radiation exposure during contemporary conformal breast cancer radiotherapy. These data emphasize the importance of radiotherapy techniques that limit MCRD during breast cancer treatment. Moreover, these data provide further support for the importance of coronary microvascular compromise in the pathophysiology of HFpEF.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Saiki H, Petersen IA, Scott CG, et al. Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer. Circulation. 2017. PMID: 28132957. doi:10.1161/CIRCULATIONAHA.116.025434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。